Dimerix Limited announced that the first patients have been dosed in India in the CLARITY 2.0 feasibility/Phase 3 study of DMX-200 as a potential new treatment for respiratory complications associated with COVID-19. Multiple sites had been initiated in India following regulatory approval from the Indian regulatory agency, the Central Drugs Standard Control Organization (DCGI),1 and shipment of DMX-200 drug supply to India from Dimerix' US based manufacturer. An interim safety analysis is planned after the first 80 patients recruited in India in the 600-patient study, which expected to occur in the first quarter of 2022.

The study also plans to recruit COVID-19 patients in Australia, 5 for which ethics approval was received in December 2021.